Anti-CD47 Antibody Dosing Regimen for Rituximab-Refractory Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating CD20+ B cell cancers, such as Non-Hodgkin's lymphoma, are limited by resistance to rituximab and other therapies, necessitating the development of novel approaches to enhance cancer cell elimination.
Innovation Solution
The use of an anti-CD47 antibody, Hu5F9-G4, in combination with rituximab, administered according to a specific dosing regimen involving priming and maintenance doses, to effectively target and eliminate CD20+ B cell cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD47 antibody is administered alone, then CD47 receptor saturation is achieved, but cancer cell elimination is insufficient due to resistance mechanisms
Solution Approach 1:
The patent combines anti-CD47 antibody (Hu5F9-G4) with rituximab (anti-CD20 antibody) in a synergistic combination therapy. This merging of two mechanisms of action overcomes resistance by simultaneously blocking CD47-mediated phagocytosis inhibition and CD20-mediated antibody-dependent cellular cytotoxicity, achieving superior cancer cell elimination compared to either agent alone.
Solution Approach 2:
The combination therapy creates a composite therapeutic effect where the anti-CD47 antibody and rituximab work together to enhance cancer cell removal. The composite approach leverages the complementary mechanisms of both antibodies to overcome therapeutic resistance and improve overall treatment efficacy in CD20+ B cell cancers.
2Reliability
If rituximab is used for treatment, then CD20+ B cell cancer is targeted, but treatment failure occurs in refractory patients
Solution Approach 1:
The anti-CD47 antibody serves as an intermediary that enhances the effectiveness of rituximab in refractory patients. By blocking CD47, the anti-CD47 antibody removes the inhibitory signal that prevents phagocytosis, thereby amplifying the cytotoxic effect of rituximab-mediated antibody-dependent cellular cytotoxicity and achieving response in previously refractory cases.
Solution Approach 2:
The anti-CD47 antibody is administered as a priming dose followed by maintenance doses that prepare the immune system for enhanced response. This preliminary action of CD47 blocking sensitizes the system to subsequent rituximab treatment, enabling effective cancer cell elimination in refractory patients who would not respond to rituximab alone.
3Reliability
If combination therapy is administered, then cancer cell elimination is enhanced, but dosing complexity increases
Solution Approach 1:
The dosing regimen is segmented into distinct phases: a priming dose of anti-CD47 antibody administered on Day 1, followed by maintenance doses on Days 8-11, and concurrent rituximab administration. This segmentation allows for optimized pharmacokinetics and pharmacodynamics, achieving enhanced cancer cell elimination while managing dosing complexity through structured administration schedules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy achieves significant receptor saturation of CD47, leading to enhanced phagocytosis of cancer cells and improved clinical outcomes, including objective responses and disease control, even in rituximab-refractory patients.
Implementation Method 1
When SIRPα is activated by CD47 binding, it initiates a signal transduction cascade resulting in inhibition of phagocytosis
Implementation Method 2
CD47-blocking antibodies inhibit human cancer growth and metastasis by enabling phagocytosis and elimination of cancer cells
Implementation Method 3
Genentech: 'Rituxan and Rituxan Hycela dosing and administration brochure' describes dosing and administration regimens for Rituxan and Rituxan Hycela
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Methods, kits, and compositions are provided herein that can be used to treat CD20+ cancer using an anti-CD47 agent such as an antibody. The anti-CD47 agent can be used alone or in combination with one or more additional agent such as an anti-CD20 antibody.